Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. SYNLAB AG
  6. News
  7. Summary
    SYAB   DE000A2TSL71

SYNLAB AG

(SYAB)
  Report
Delayed Quote. Delayed Deutsche Boerse AG - 11/26 06:35:35 am
22.8 EUR   +8.57%
11/25SYNLAB : Goldman Sachs maintains a Buy rating
MD
11/25Fitch Affirms Inovie at 'B' after TLB Add-on; Outlook Stable
AQ
11/11SYNLAB : JP Morgan sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: SYNLAB expands partnership with Feedtrail to gain real-time patient and customer feedback

10/04/2021 | 03:01am EST

DGAP-News: SYNLAB AG / Key word(s): Alliance SYNLAB expands partnership with Feedtrail to gain real-time patient and customer feedback 2021-10-04 / 08:59 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

SYNLAB AG Moosacher Straße 88 80809 Munich Germany Feedtrail 5540 Centerview Drive, Suite 411 Raleigh, NC 27606 United States

Munich / Raleigh, NC (USA), 4 October 2021

SYNLAB expands partnership with Feedtrail to gain real-time patient and customer feedback . SYNLAB rolls-out Feedtrail XM platform across more than 2,000 sites in 36 countries to maintain acontinuous dialogue with patients and customers and improve day-to-day processes.

SYNLAB, Europe's leading medical diagnostic services provider, and Feedtrail, innovators in patient engagement, announce the expansion of their successful partnership to support patient and customer centricity. Committing to Feedtrail as a long-term strategic partner, SYNLAB aims to further elevate its customer experience, expanding usage of the Feedtrail XM platform across 2,100 sites in 36 countries.

Leveraging the Feedtrail XM platform, hospitals, clinicians, and patients can evaluate the service provided by SYNLAB in real-time and provide candid feedback. This way, SYNLAB maintains a continuous dialogue with patients and customers and can use real-time data to improve day-to-day processes related to patient and customer experience.

"By continuing our partnership with Feedtrail, we give our patients and customers a strong voice and strengthen our customer centric approach towards medical diagnostics. We are using insights gained on a daily basis to continuously improve our operations further. We are passionate about serving the needs of our customers to create real added value for patients and healthcare professionals," says Alexander Hagen, Head of Group Marketing and Communication at SYNLAB.

"Since day one, SYNLAB has been the epitome of an innovative medical diagnostic services provider, truly committed to prioritizing patient-centricity. This partnership is more than just improving results at SYNLAB, it's about showing how one organization can pave the way to putting patients and customers at the center of care across 36 countries over 4 continents," says Paul Jaglowski, Co-Founder and Chief Strategy Officer at Feedtrail.

The implementation of the Feedtrail XM platform will ensure data storage in EU under the highest data protection standards in line with the EU's General Data Protection Regulation. For more information:

Media contact SYNLAB:        +49 (0) 151 466 938 56 
Diana Tabor, FTI Consulting  Media-contact@synlab.com 
Investor contact SYNLAB:     +49 (0) 170 118 3753 
Mark Reinhard, SYNLAB        Mark.Reinhard@synlab.com 
Media contact Feedtrail:     + 1 919 366 7523 
Ashley Worrall               pr@feedtrail.com About SYNLAB . SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medicaldiagnostic services company and offers a full range of innovative and reliable medical diagnostics for patients,practising doctors, clinics and the pharmaceutical industry. . Providing the leading level of service within the industry, SYNLAB is the partner of choice fordiagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for thebenefit of patients and customers. . SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. Morethan 20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such asbiologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLABcarries out 500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020. . More information can be found on www.synlab.com About Feedtrail . With Feedtrail XM, healthcare organizations can learn and deliver what matters most to patients,providers, caregivers, and employees. . Our secure, cloud-based experience management (XM) solutions and advanced data analytics enable customerexperience teams to engage and connect with the right people at the right time, uncover prescriptive insights, andtake purposeful action to drive continuous improvement and measurable results across the lifecycle of care. . Over 70 innovative health systems across 4,000 sites in 14 countries already use Feedtrail to uncoverexplicit opportunities to improve human-centered care and advance better outcomes for people and the business ofhealthcare. . Learn more www.feedtrail.com. You can also follow us on LinkedIn, Facebook and Twitter. 

-----------------------------------------------------------------------------------------------------------------------

2021-10-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1237679 
 
End of News   DGAP News Service 
=------------ 

1237679 2021-10-04

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1237679&application_name=news

(END) Dow Jones Newswires

October 04, 2021 03:00 ET (07:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
FACEBOOK INC -2.33% 333.12 Delayed Quote.21.95%
FTI CONSULTING, INC. -2.18% 146.52 Delayed Quote.31.15%
SYNLAB AG 8.57% 22.8 Delayed Quote.0.00%
All news about SYNLAB AG
11/25SYNLAB : Goldman Sachs maintains a Buy rating
MD
11/25Fitch Affirms Inovie at 'B' after TLB Add-on; Outlook Stable
AQ
11/11SYNLAB : JP Morgan sticks Neutral
MD
11/11SYNLAB : Deutsche Bank reiterates its Buy rating
MD
11/10SYNLAB : Barclays reaffirms its Neutral rating
MD
11/10SYNLAB : Goldman Sachs keeps its Buy rating
MD
11/10SYNLAB : JP Morgan reaffirms its Neutral rating
MD
11/10SYNLAB : Jefferies reaffirms its Buy rating
MD
11/10SYNLAB Boosts FY21 Outlook from IPO Goals
MT
11/10SYNLAB delivers strong 9M 2021 results, on track to significantly exceed 2021 financial..
EQ
More news
Analyst Recommendations on SYNLAB AG
More recommendations
Financials
Sales 2021 3 580 M 4 045 M 4 045 M
Net income 2021 546 M 617 M 617 M
Net Debt 2021 1 555 M 1 757 M 1 757 M
P/E ratio 2021 9,47x
Yield 2021 2,61%
Capitalization 5 067 M 5 733 M 5 725 M
EV / Sales 2021 1,85x
EV / Sales 2022 2,24x
Nbr of Employees 22 000
Free-Float 75,7%
Chart SYNLAB AG
Duration : Period :
SYNLAB AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 22,80 €
Average target price 24,24 €
Spread / Average Target 6,32%
EPS Revisions
Managers and Directors
Mathieu Olivier Floreani Chairman-Management Board & CEO
Sami Badarani Chief Financial Officer & Finance Director
David Raymond Ebsworth Chairman-Supervisory Board
Valor Garcia Santiago Chief Medical Officer
Henrik Andreasen Chief Information Officer
Sector and Competitors